<DOC>
	<DOCNO>NCT00387530</DOCNO>
	<brief_summary>RATIONALE : The Epstein-Barr virus cause cancer lymphoproliferative disorder . Valganciclovir antiviral drug act Epstein-Barr virus . Phenylbutyrate may make cell infect Epstein-Barr virus sensitive valganciclovir . Giving phenylbutyrate together valganciclovir may block growth Epstein-Barr virus-infected cell kill cancer cell . PURPOSE : This phase II trial study well give phenylbutyrate together valganciclovir work treat patient relapsed refractory Epstein-Barr virus-positive cancer .</brief_summary>
	<brief_title>Phenylbutyrate Valganciclovir Treating Patients With Relapsed Refractory Epstein-Barr Virus-Positive Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine rate Epstein-Barr virus ( EBV ) lytic phase activation BZLF1 expression patient relapse refractory , EBV-positive malignancy treat phenylbutyrate . Secondary - Determine tumor responses patient treated phenylbutyrate follow valganciclovir . - Track serum EBV load quantitative polymerase chain reaction correlate change EBV lytic phase activation/tumor response . OUTLINE : This open-label study . Patients receive oral phenylbutyrate three time daily day 1-21 oral valganciclovir twice daily day 4-21 . Treatment repeat every 21 day 2 year absence disease progression unacceptable toxicity . Patients undergo biopsy day 3 course 1 . Serum Epstein-Barr virus DNA analyze expression BZLF1 LMP2 quantitative polymerase chain reaction day 3 14 course 1 day 1 subsequent course . After completion study treatment , patient follow 1 3 month . PROJECTED ACCRUAL : A total 14 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven EpsteinBarr virus ( EBV ) positive malignancy Must tissue analysis confirm EBV positivity Archival tissue ≤ 1 year old may use Any following malignancy : WHO type II III nasopharyngeal carcinoma Posttransplant lymphoproliferative disorder Nasal NK/Tcell lymphoma Hodgkin 's lymphoma Lymphoepitheliomavariant gastric carcinoma AIDSrelated lymphoma Patients CNS nonHodgkin 's lymphoma must tumor cell present cerebrospinal fluid ( assessable lumbar puncture ) Relapsed refractory disease Must receive fail prior potentially curative treatment disease Eligible salvage therapy Must tumor tissue amenable minimally invasive biopsy ( e.g. , fineneedle aspiration bone marrow biopsy ) No brain tumor amenable biopsy CNS metastases allow provide ≥ 2 week since prior radiotherapy PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month Absolute granulocyte count ≥ 500/mm³ Platelet count ≥ 50,000/mm³ Bilirubin ≤ 1.5 time upper limit normal Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min Recovered uncontrolled intercurrent illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Able take medication orally gastrostomy tube Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior , , 90 day completion study treatment No uncontrolled grade 1 symptomatic diarrhea ( i.e. , &gt; 3 stools/day ) No concurrent serious medical psychiatric illness would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics Concurrent cerebrospinal fluid drug allow No concurrent zidovudine HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>recurrent gastric cancer</keyword>
</DOC>